KBI Biopharma Executive and Leadership Team

Katherine Wolf, the Chief Financial Officer at KBI Biopharma, manages the fiscal health and long-term capital allocation strategies for the organization. Overseeing financial planning and analysis, the Chief Financial Officer ensures that investments in specialized technologies and facility expansions align with corporate growth objectives. This leadership role involves monitoring revenue streams from integrated development services and maintaining robust financial reporting standards. By evaluating market trends in the biologics sector, Katherine Wolf directly impacts the company's competitive positioning and resource distribution. Wolf coordinates with the executive team to assess the financial viability of new service offerings and potential market entries. Through rigorous budget management and risk assessment, the Chief Financial Officer supports the sustainability of the business model. Ultimately, Wolf provides the financial foundation necessary for the company to continue accelerating the development of life-saving vaccines and complex therapeutic products.

Peter Carbone, the Chief Operating Officer at KBI Biopharma, directs all internal manufacturing operations and process development workflows. Overseeing the global production network, the Chief Operating Officer ensures that complex biologics meet rigorous quality standards while maintaining efficient output cycles. This leadership role involves optimizing the integration of cell line development and analytical characterization services to support client timelines. By streamlining cross-functional workflows, Peter Carbone directly impacts the company's ability to scale production for life sciences partners. Carbone manages the technical infrastructure required for clinical and commercial manufacturing, ensuring that facilities operate at peak performance. Through the implementation of advanced manufacturing technologies, the Chief Operating Officer drives operational excellence across all sites. Ultimately, Carbone secures the reliability of the supply chain, enabling the rapid delivery of innovative medicines and vaccines to the global market.

Toshihiro Ogawa, the President, Kbi Biopharma (Japan) at KBI Biopharma, directs all business operations and strategic growth initiatives within the Japanese market. Overseeing regional expansion, the President, Kbi Biopharma (Japan) ensures that local life sciences companies gain seamless access to the company's integrated development and manufacturing services. This leadership role involves building strong partnerships with regional pharmaceutical firms and navigating the specific regulatory landscape of the biologics sector. By tailoring service delivery to meet local market demands, Toshihiro Ogawa directly impacts the company's footprint in the Asia-Pacific region. Ogawa coordinates with global leadership to integrate regional insights into the broader corporate strategy for complex biologics production. Through the development of local client relationships and the oversight of regional service quality, the President, Kbi Biopharma (Japan) drives revenue growth and brand recognition. Ultimately, Ogawa secures the company's influence in the critical Japanese market.

Debra Bruneau, the Chief People Officer at KBI Biopharma, directs the human capital strategy and organizational development initiatives. Overseeing talent acquisition and employee engagement, the Chief People Officer ensures that the company attracts and retains top-tier scientific talent capable of executing complex biologics manufacturing. This leadership role involves fostering a culture of innovation and technical excellence across all global departments. By designing comprehensive training programs and performance management systems, Debra Bruneau directly impacts the operational capacity of the workforce. Bruneau aligns human resources policies with the broader mission of accelerating medicine development, ensuring that teams remain focused on client success. Through the cultivation of a diverse and skilled workforce, the Chief People Officer drives the internal capabilities required for high-level analytical and formulation development. Ultimately, Bruneau secures the organizational strength needed to maintain a leading position within the competitive life sciences manufacturing industry.